FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Moderna Slows Trail After Failing to Include Enough Minority Participants”
Moderna, Inc. (NASDAQ: MRNA) slowed enrollment of its late-stage trial due to a failure to recruit enough minority volunteers, sending the stock higher in early morning trading
Private contractors hired by the company failed to enroll enough Black, Latino and Native American participants, prompting concerns the trial would fail to accurately track how well the vaccine would work within these populations.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.
For more information, please visit: Moderna, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.